tirzepatide and epilepsy In adults with obesity but not diabetes, leads to significantly greater weight loss than semaglutide over 72 weeks, nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL New epilepsy therapies in development

Semaglutide: Mechanism of Action and Clinical Value Mechanism of Action Semaglutide belongs to the class of GLP-1 receptor agonists (glucagon-like peptide-1), designed to mimic natural incretin hormones involved in glucose regulation and appetite control

These options include: Zepbound (Tirzepatide Injection) Zepbound offers a weekly injection that combines GLP-1 and GIP receptor activation, backed by significant clinical trial results

What milestones did you achieve, and what wellness goals will you set for the upcoming year

PMC11241973 Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia

It's built specifically for adults whose bodies are changing under GLP-1 medication and need supervised training to protect lean tissue, bone density, and metabolic health

This shift empowers individuals to take control of their health, with the rapid adoption of GLP-1 receptor agonists like Semaglutide and Tirzepatide at its center